Latest Content


Gilead’s Yescarta Demonstrates Improvement in Overall Survival for Aggressive Blood Cancers

Kite’s Yescarta CAR-T cell therapy has demonstrated significant improvement for the treatment of relapsed/refractory large B-cell lymphoma from its Phase III ZUMA trial.
23rd Mar 2023

Autologous vs Allogeneic: What Therapeutic Developers and Manufacturers Really Need to Know

Rupa Pike, Senior Director of Technical Affairs, Advanced Therapies, Thermo Fisher Scientific, joined us live at Advanced Therapies Week 2023 to discuss and shed some light on the current autologous vs allogeneic cell therapy landscape.
16th Mar 2023

GOSH Enters into Agreement with Leucid Bio at a New Therapy Manufacturing Center

Leucid Bio, announced an agreement with Great Ormond Street Hospital (GOSH) to manufacture its lead asset CAR-T cell therapy LEU011, for use in human clinical studies.
16th Mar 2023

Pfizer Invests $43 Billion to Acquire Seagen

Pfizer is to acquire global technology company Seagan in a definitive merger agreement for a total enterprise value of $43 billion.
14th Mar 2023

Adaptimmune and TCR2 Collaborate to Develop Cell Therapies for Solid Tumors

Adaptimmune Theraputics and TCR2 Theraputics have announced they are to combine to create a preeminent cell therapy company developing potential treatments for solid tumors.
8th Mar 2023

Coffee and a Cupcake: a Spotlight on Women in Advanced Therapies

Becky Johnson-Kent, Program Lead for Phacilitate’s Women in Advanced Therapies, is joined by Audrey Greenberg, Founder of the Center for Breakthrough Medicines, Jacqueline Barry, Chief Clinical Officer at Cell and Gene Therapy Catapult, Lindsey Clarke, Co-Founder of the CGT Circle and Susan Nichols, Chief Business Officer at Virocell to discuss the challenges still facing women within the advanced therapies industry, and what’s needed to overcome them. 
8th Mar 2023

Don’t Miss Out on Our Latest Webinar

Upcoming Event

Up Next: Manufacture of Healthy and Highly Functioning Gene-Edited Immune Cells

Are you looking to engineer your cells to manufacture healthy and highly functioning immune cells? 
08:00 PDT | 11:00 EDT | 16:00 GMT

Access Our Webinar Library

Our eBooks & Infographics
Gene-edited cell therapies represent a rapidly growing area for advanced therapeutic development, but manufacturing-related challenges remain to commercialize such complex therapies.
This Case Study demonstrates how the Excellos team successfully carried out process development of a scale up procedure from tissue culture stacks to a commercial bioreactor system.
This Case Study demonstrates how the use of Akadeum’s microbubble platform offers a simple and highly tunable isolation and activation workflow that generates T cells ready for suspended cell culture and downstream applications, such as genetic modification and expansion, and discusses the potential impact of the solution on cancer treatment. 
What are the steps on the long and winding road from the lab bench to the clinic for a novel gene therapy?
The Phacilitate team is delighted to present this eBook, in partnership with WuXi Advanced Therapies, as a comprehensive resource for gene therapy development.
In this infographic, we have detailed some key considerations when choosing your plasmids for CAR-T development.
As we celebrate 10 years of CAR-T, the Phacilitate team is delighted to present this eBook, in partnership with WuXi Advanced Therapies, as a comprehensive resource for CAR-T development.
Gaining market and patient access in Europe has presented many cell and gene therapy companies with barriers. The advanced therapies industry is currently facing a dilemma: scientific advancement is exceeding market and reimbursement adaptation.
Advanced therapies’ market access is a hot topic. Joining Phacilitate to shed some light on market access struggles are Director at NJ Redfern Limited and ex-bluebird bio UK GM Nicola Redfern, former SVP & CBO at Novartis Gene Therapies and current AviadoBio CEO Lisa Deschamps, and, Vice President and Global Head of Value and Access, at Novartis, Tay Salimullah.
What’s preventing developers from designing mechanistically relevant assays? This report examines this question, focusing on the identification and measurement of appropriate CQAs, the value of fit-for-purpose analytics technologies and what the future of CGT manufacturing analytics should look like.